Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions - PubMed (original) (raw)

Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions

J M Trugman et al. J Neurosci. 1987 Sep.

Abstract

The relative roles of D1 and D2 dopamine receptor stimulation in mediating the antiparkinsonian effects of dopaminergic drugs remain unclear. To determine the functional metabolic consequences of selective dopamine receptor stimulation, we used 2-deoxyglucose (2-DG) autoradiography to examine the effects of the D1 agonist SKF-38393 and the D2 agonist LY-171555 on regional cerebral glucose utilization (RCGU) in rats with unilateral 6-hydroxydopamine (6-OHDA) substantia nigra lesions. SKF-38393 (0.5-25.0 mg/kg) and LY-171555 (0.01-5.0 mg/kg) produced indistinguishable behavioral responses, including vigorous contralateral rotation. Treatment with each drug similarly increased glucose utilization, dose-dependently, in the parafascicular thalamus, subthalamic nucleus, deep layers of the superior colliculus, and lateral midbrain reticular formation ipsilateral to the nigral lesion; glucose utilization was decreased in the ipsilateral lateral habenula. By contrast, the D1 and D2 agonists differentially altered glucose utilization in the entopeduncular nucleus (EP) and the substantia nigra pars reticulata (SNr). SKF-38393, 5.0 and 25.0 mg/kg, increased glucose utilization 127 and 275%, respectively, in the pars reticulata ipsilateral to the lesion. LY-171555, 1.0 and 5.0 mg/kg, caused maximal contralateral turning, yet did not alter glucose utilization in the ipsilateral SNr. The glucose utilization response of the ipsilateral EP paralleled that of the SNr demonstrating large increases following administration of SKF-38393 and minimal change following the use of LY-171555. The results demonstrate that the selective D1 agonist reproduces the marked glucose utilization increases (2-3-fold above control values) in the EP and SNr that were previously observed using L-DOPA and apomorphine in this model, whereas the selective D2 agonist does not.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Cited by

Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission.
Fremeau RT Jr, Duncan GE, Fornaretto MG, Dearry A, Gingrich JA, Breese GR, Caron MG. Fremeau RT Jr, et al. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3772-6. doi: 10.1073/pnas.88.9.3772. Proc Natl Acad Sci U S A. 1991. PMID: 2023928 Free PMC article.
Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.
Archer T, Palomo T, McArthur R, Fredriksson A. Archer T, et al. Neurotox Res. 2003;5(1-2):95-110. doi: 10.1007/BF03033375. Neurotox Res. 2003. PMID: 12832225
Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model.
Wickens J. Wickens J. J Neural Transm Gen Sect. 1990;80(1):9-31. doi: 10.1007/BF01245020. J Neural Transm Gen Sect. 1990. PMID: 2407269 Review.
D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats.
Bhattacharjee AK, Chang L, Lee HJ, Bazinet RP, Seemann R, Rapoport SI. Bhattacharjee AK, et al. Psychopharmacology (Berl). 2005 Aug;180(4):735-42. doi: 10.1007/s00213-005-2208-4. Epub 2005 Sep 14. Psychopharmacology (Berl). 2005. PMID: 16163535
Differential regulation of neuropeptide mRNA expression in intrastriatal striatal transplants by host dopaminergic afferents.
Campbell K, Wictorin K, Björklund A. Campbell K, et al. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10489-93. doi: 10.1073/pnas.89.21.10489. Proc Natl Acad Sci U S A. 1992. PMID: 1438238 Free PMC article.

Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions - PubMed (original) (raw)